For J&J OTC Sales, Tylenol Arthritis Label Approval Could Bring Relief Closer
This article was originally published in The Tan Sheet
Executive Summary
FDA’s approval positions J&J/McNeil to return Tylenol 8HR Arthritis to the market with new packaging to interest consumers while also sustaining their connection with the iconic brand. The latest label design for the product features different color schemes and text fonts than the most recent previous changes.
You may also be interested in...
J&J Bit Off More Than McNeil Could Chew In 2006 Pfizer OTC Acquisition
McNeil scaled up its manufacturing “volume and complexity substantially” following J&J’s acquisition of Pfizer’s consumer business in 2006, says McNeil Consumer VP Shane Freedman. “Just a few years later, we had the recalls” that led eventually to a consent decree with FDA,” he says.
J&J Will Boost OTC Marketing Once Reliable Production Returns
Johnson & Johnson CEO Alex Gorsky says he expects 75% of OTC products previously recalled to be back on the market in 2013, and the firm will begin prioritizing marketing efforts once a consistent supply of products is restored. The McNeil Fort Washington facility will remain offline another year.
Jurors' Answers In FTC's Prevagen Complaint Might Burst A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.